Global Blood Cancer Drugs research

Blood Cancer Drugs Comprehensive Study by Drugs (Rituaxan, Revlimid, Velcade, Vidaza, Pomalyst, Others), Treatment Approaches (Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic), Blood Cancer Type (Leukemia, Lymphoma, Myeloma) Players and Region - Global Market Outlook to 2028

Blood Cancer Drugs Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Blood cancer is defined as cancer that initiates in blood-forming tissue and it also affects bone marrow and cells of the immune system. Lymphoma, leukemia, and multiple myeloma are some of the major diseases of blood cancer. The major symptoms of blood cancer are chest pain, chills, Loss of appetite, persistent weakness, and fatigue, among others. In 2018, according to an article published by the National Cancer Institute (United States), more than 1,735,350 new cases of cancer are diagnosed in the United States. Hence, the rising number of cancer patients globally and raising awareness of blood cancer drugs are some of the major factors which affect the growth of the market in the future.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledJohnson & Johnson Inc. (United States), Amgen Inc. (United States), Bayer AG (Germany), Pfizer, Inc. (United States), AbbVie Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Celgene Corporation (Switzerland), AstraZeneca plc (United Kingdom), Novartis International AG (Switzerland) and GlaxoSmithKline PLC (United Kingdom)


This growth is primarily driven by Rising Prevalence of Cancer Epidemics and Growing Geriatric Population Base Worldwide and Increasing Number of Cancer Patients, Which Has Led to Rising Demand for Cancer Drugs.

Globally, a noticeable market trend is evident Increasing Investment in Research & Development globally, For instance, Leukemia & Lymphoma Society (United States), has Investing Huge Amounts in Cure Blood Cancer The Pharmaceuticals sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Johnson & Johnson Inc. (United States), Amgen Inc. (United States), Bayer AG (Germany), Pfizer, Inc. (United States), AbbVie Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Celgene Corporation (Switzerland), AstraZeneca plc (United Kingdom), Novartis International AG (Switzerland) and GlaxoSmithKline PLC (United Kingdom), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The market appears to be highly fragmented and with the presence of several companies including Johnson & Johnson Inc. (United States), Amgen Inc. (United States), Bayer AG (Germany), among others

Key Developments in the Market:
In June 2021, AbbVie acquired the TeneoOne and its key immunotherapeutic asset for treating blood cancer named TNB-383B. TNB-383B is a bispecific antibody that targets both BCMA and CD3 and is designed to direct the body's own immune system to target and kill BCMA-expressing tumor cells.
In April 2019, the Emcure Pharmaceutical (India) Company launched generic breast cancer medicine, which is used to treat HER 2 negative patients. Hence, it will benefit the increased product portfolio of the company in the future.

Regulatory Insights:
In the European Union, the European Medicines Agency (EMA) plays a key role in the regulation of blood cancer drugs. The EMA evaluates the safety, efficacy, and quality of these drugs through a centralized procedure that grants marketing authorization to the European Union.

Influencing Trend:
Increasing Investment in Research & Development globally, For instance, Leukemia & Lymphoma Society (United States), has Investing Huge Amounts in Cure Blood Cancer

Market Growth Drivers:
Rising Prevalence of Cancer Epidemics and Growing Geriatric Population Base Worldwide and Increasing Number of Cancer Patients, Which Has Led to Rising Demand for Cancer Drugs

Challenges:
High Cost of Drug Development and the Threat of Failure

Restraints:
Issue related to adverse Effects Associated with the use of Blood Cancer Drugs

Opportunities:
High Growth Potential in Developing Countries especially China & India, which has also led to a Rise in Demand for Cancer Drugs in the Future and Government initiative to promote the Treatment of Blood Cancer Disease

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Blood Cancer Drugs Market
- Analysis about New Entrants in Blood Cancer Drugs Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Blood Cancer Drugs Study Sheds Light on
— The Blood Cancer Drugs Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Blood Cancer Drugs industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Blood Cancer Drugs industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Drugs
  • Rituaxan
  • Revlimid
  • Velcade
  • Vidaza
  • Pomalyst
  • Others

By Treatment Approaches
  • Chemotherapeutic
  • MAbs/Targeted Therapies
  • Immunotherapeutic

By Blood Cancer Type
  • Leukemia
  • Lymphoma
  • Myeloma

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Cancer Epidemics and Growing Geriatric Population Base Worldwide
      • 3.2.2. Increasing Number of Cancer Patients, Which Has Led to Rising Demand for Cancer Drugs
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Drug Development and the Threat of Failure
    • 3.4. Market Trends
      • 3.4.1. Increasing Investment in Research & Development globally, For instance, Leukemia & Lymphoma Society (United States), has Investing Huge Amounts in Cure Blood Cancer
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Blood Cancer Drugs, by Drugs, Treatment Approaches, Blood Cancer Type and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Blood Cancer Drugs (Value)
      • 5.2.1. Global Blood Cancer Drugs by: Drugs (Value)
        • 5.2.1.1. Rituaxan
        • 5.2.1.2. Revlimid
        • 5.2.1.3. Velcade
        • 5.2.1.4. Vidaza
        • 5.2.1.5. Pomalyst
        • 5.2.1.6. Others
      • 5.2.2. Global Blood Cancer Drugs by: Treatment Approaches (Value)
        • 5.2.2.1. Chemotherapeutic
        • 5.2.2.2. MAbs/Targeted Therapies
        • 5.2.2.3. Immunotherapeutic
      • 5.2.3. Global Blood Cancer Drugs by: Blood Cancer Type (Value)
        • 5.2.3.1. Leukemia
        • 5.2.3.2. Lymphoma
        • 5.2.3.3. Myeloma
      • 5.2.4. Global Blood Cancer Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Blood Cancer Drugs (Volume)
      • 5.3.1. Global Blood Cancer Drugs by: Drugs (Volume)
        • 5.3.1.1. Rituaxan
        • 5.3.1.2. Revlimid
        • 5.3.1.3. Velcade
        • 5.3.1.4. Vidaza
        • 5.3.1.5. Pomalyst
        • 5.3.1.6. Others
      • 5.3.2. Global Blood Cancer Drugs by: Treatment Approaches (Volume)
        • 5.3.2.1. Chemotherapeutic
        • 5.3.2.2. MAbs/Targeted Therapies
        • 5.3.2.3. Immunotherapeutic
      • 5.3.3. Global Blood Cancer Drugs by: Blood Cancer Type (Volume)
        • 5.3.3.1. Leukemia
        • 5.3.3.2. Lymphoma
        • 5.3.3.3. Myeloma
      • 5.3.4. Global Blood Cancer Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Blood Cancer Drugs (Price)
  • 6. Blood Cancer Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson & Johnson Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Amgen Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AbbVie Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Celgene Corporation (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AstraZeneca plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis International AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Blood Cancer Drugs Sale, by Drugs, Treatment Approaches, Blood Cancer Type and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Blood Cancer Drugs (Value)
      • 7.2.1. Global Blood Cancer Drugs by: Drugs (Value)
        • 7.2.1.1. Rituaxan
        • 7.2.1.2. Revlimid
        • 7.2.1.3. Velcade
        • 7.2.1.4. Vidaza
        • 7.2.1.5. Pomalyst
        • 7.2.1.6. Others
      • 7.2.2. Global Blood Cancer Drugs by: Treatment Approaches (Value)
        • 7.2.2.1. Chemotherapeutic
        • 7.2.2.2. MAbs/Targeted Therapies
        • 7.2.2.3. Immunotherapeutic
      • 7.2.3. Global Blood Cancer Drugs by: Blood Cancer Type (Value)
        • 7.2.3.1. Leukemia
        • 7.2.3.2. Lymphoma
        • 7.2.3.3. Myeloma
      • 7.2.4. Global Blood Cancer Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Blood Cancer Drugs (Volume)
      • 7.3.1. Global Blood Cancer Drugs by: Drugs (Volume)
        • 7.3.1.1. Rituaxan
        • 7.3.1.2. Revlimid
        • 7.3.1.3. Velcade
        • 7.3.1.4. Vidaza
        • 7.3.1.5. Pomalyst
        • 7.3.1.6. Others
      • 7.3.2. Global Blood Cancer Drugs by: Treatment Approaches (Volume)
        • 7.3.2.1. Chemotherapeutic
        • 7.3.2.2. MAbs/Targeted Therapies
        • 7.3.2.3. Immunotherapeutic
      • 7.3.3. Global Blood Cancer Drugs by: Blood Cancer Type (Volume)
        • 7.3.3.1. Leukemia
        • 7.3.3.2. Lymphoma
        • 7.3.3.3. Myeloma
      • 7.3.4. Global Blood Cancer Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Blood Cancer Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Blood Cancer Drugs: by Drugs(USD Million)
  • Table 2. Blood Cancer Drugs Rituaxan , by Region USD Million (2017-2022)
  • Table 3. Blood Cancer Drugs Revlimid , by Region USD Million (2017-2022)
  • Table 4. Blood Cancer Drugs Velcade , by Region USD Million (2017-2022)
  • Table 5. Blood Cancer Drugs Vidaza , by Region USD Million (2017-2022)
  • Table 6. Blood Cancer Drugs Pomalyst , by Region USD Million (2017-2022)
  • Table 7. Blood Cancer Drugs Others , by Region USD Million (2017-2022)
  • Table 8. Blood Cancer Drugs: by Treatment Approaches(USD Million)
  • Table 9. Blood Cancer Drugs Chemotherapeutic , by Region USD Million (2017-2022)
  • Table 10. Blood Cancer Drugs MAbs/Targeted Therapies , by Region USD Million (2017-2022)
  • Table 11. Blood Cancer Drugs Immunotherapeutic , by Region USD Million (2017-2022)
  • Table 12. Blood Cancer Drugs: by Blood Cancer Type(USD Million)
  • Table 13. Blood Cancer Drugs Leukemia , by Region USD Million (2017-2022)
  • Table 14. Blood Cancer Drugs Lymphoma , by Region USD Million (2017-2022)
  • Table 15. Blood Cancer Drugs Myeloma , by Region USD Million (2017-2022)
  • Table 16. South America Blood Cancer Drugs, by Country USD Million (2017-2022)
  • Table 17. South America Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 18. South America Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 19. South America Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 20. Brazil Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 21. Brazil Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 22. Brazil Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 23. Argentina Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 24. Argentina Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 25. Argentina Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 26. Rest of South America Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 27. Rest of South America Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 28. Rest of South America Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 29. Asia Pacific Blood Cancer Drugs, by Country USD Million (2017-2022)
  • Table 30. Asia Pacific Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 31. Asia Pacific Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 32. Asia Pacific Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 33. China Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 34. China Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 35. China Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 36. Japan Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 37. Japan Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 38. Japan Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 39. India Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 40. India Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 41. India Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 42. South Korea Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 43. South Korea Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 44. South Korea Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 45. Taiwan Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 46. Taiwan Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 47. Taiwan Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 48. Australia Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 49. Australia Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 50. Australia Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 54. Europe Blood Cancer Drugs, by Country USD Million (2017-2022)
  • Table 55. Europe Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 56. Europe Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 57. Europe Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 58. Germany Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 59. Germany Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 60. Germany Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 61. France Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 62. France Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 63. France Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 64. Italy Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 65. Italy Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 66. Italy Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 67. United Kingdom Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 68. United Kingdom Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 69. United Kingdom Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 70. Netherlands Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 71. Netherlands Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 72. Netherlands Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 73. Rest of Europe Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 74. Rest of Europe Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 75. Rest of Europe Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 76. MEA Blood Cancer Drugs, by Country USD Million (2017-2022)
  • Table 77. MEA Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 78. MEA Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 79. MEA Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 80. Middle East Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 81. Middle East Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 82. Middle East Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 83. Africa Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 84. Africa Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 85. Africa Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 86. North America Blood Cancer Drugs, by Country USD Million (2017-2022)
  • Table 87. North America Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 88. North America Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 89. North America Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 90. United States Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 91. United States Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 92. United States Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 93. Canada Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 94. Canada Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 95. Canada Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 96. Mexico Blood Cancer Drugs, by Drugs USD Million (2017-2022)
  • Table 97. Mexico Blood Cancer Drugs, by Treatment Approaches USD Million (2017-2022)
  • Table 98. Mexico Blood Cancer Drugs, by Blood Cancer Type USD Million (2017-2022)
  • Table 99. Blood Cancer Drugs Sales: by Drugs(k Tons)
  • Table 100. Blood Cancer Drugs Sales Rituaxan , by Region k Tons (2017-2022)
  • Table 101. Blood Cancer Drugs Sales Revlimid , by Region k Tons (2017-2022)
  • Table 102. Blood Cancer Drugs Sales Velcade , by Region k Tons (2017-2022)
  • Table 103. Blood Cancer Drugs Sales Vidaza , by Region k Tons (2017-2022)
  • Table 104. Blood Cancer Drugs Sales Pomalyst , by Region k Tons (2017-2022)
  • Table 105. Blood Cancer Drugs Sales Others , by Region k Tons (2017-2022)
  • Table 106. Blood Cancer Drugs Sales: by Treatment Approaches(k Tons)
  • Table 107. Blood Cancer Drugs Sales Chemotherapeutic , by Region k Tons (2017-2022)
  • Table 108. Blood Cancer Drugs Sales MAbs/Targeted Therapies , by Region k Tons (2017-2022)
  • Table 109. Blood Cancer Drugs Sales Immunotherapeutic , by Region k Tons (2017-2022)
  • Table 110. Blood Cancer Drugs Sales: by Blood Cancer Type(k Tons)
  • Table 111. Blood Cancer Drugs Sales Leukemia , by Region k Tons (2017-2022)
  • Table 112. Blood Cancer Drugs Sales Lymphoma , by Region k Tons (2017-2022)
  • Table 113. Blood Cancer Drugs Sales Myeloma , by Region k Tons (2017-2022)
  • Table 114. South America Blood Cancer Drugs Sales, by Country k Tons (2017-2022)
  • Table 115. South America Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 116. South America Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 117. South America Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 118. Brazil Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 119. Brazil Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 120. Brazil Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 121. Argentina Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 122. Argentina Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 123. Argentina Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 124. Rest of South America Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 125. Rest of South America Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 126. Rest of South America Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 127. Asia Pacific Blood Cancer Drugs Sales, by Country k Tons (2017-2022)
  • Table 128. Asia Pacific Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 129. Asia Pacific Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 130. Asia Pacific Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 131. China Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 132. China Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 133. China Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 134. Japan Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 135. Japan Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 136. Japan Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 137. India Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 138. India Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 139. India Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 140. South Korea Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 141. South Korea Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 142. South Korea Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 143. Taiwan Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 144. Taiwan Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 145. Taiwan Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 146. Australia Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 147. Australia Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 148. Australia Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 149. Rest of Asia-Pacific Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 150. Rest of Asia-Pacific Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 151. Rest of Asia-Pacific Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 152. Europe Blood Cancer Drugs Sales, by Country k Tons (2017-2022)
  • Table 153. Europe Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 154. Europe Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 155. Europe Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 156. Germany Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 157. Germany Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 158. Germany Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 159. France Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 160. France Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 161. France Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 162. Italy Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 163. Italy Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 164. Italy Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 165. United Kingdom Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 166. United Kingdom Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 167. United Kingdom Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 168. Netherlands Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 169. Netherlands Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 170. Netherlands Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 171. Rest of Europe Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 172. Rest of Europe Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 173. Rest of Europe Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 174. MEA Blood Cancer Drugs Sales, by Country k Tons (2017-2022)
  • Table 175. MEA Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 176. MEA Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 177. MEA Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 178. Middle East Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 179. Middle East Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 180. Middle East Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 181. Africa Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 182. Africa Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 183. Africa Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 184. North America Blood Cancer Drugs Sales, by Country k Tons (2017-2022)
  • Table 185. North America Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 186. North America Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 187. North America Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 188. United States Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 189. United States Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 190. United States Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 191. Canada Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 192. Canada Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 193. Canada Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 194. Mexico Blood Cancer Drugs Sales, by Drugs k Tons (2017-2022)
  • Table 195. Mexico Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2017-2022)
  • Table 196. Mexico Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2017-2022)
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Blood Cancer Drugs: by Drugs(USD Million)
  • Table 208. Blood Cancer Drugs Rituaxan , by Region USD Million (2023-2028)
  • Table 209. Blood Cancer Drugs Revlimid , by Region USD Million (2023-2028)
  • Table 210. Blood Cancer Drugs Velcade , by Region USD Million (2023-2028)
  • Table 211. Blood Cancer Drugs Vidaza , by Region USD Million (2023-2028)
  • Table 212. Blood Cancer Drugs Pomalyst , by Region USD Million (2023-2028)
  • Table 213. Blood Cancer Drugs Others , by Region USD Million (2023-2028)
  • Table 214. Blood Cancer Drugs: by Treatment Approaches(USD Million)
  • Table 215. Blood Cancer Drugs Chemotherapeutic , by Region USD Million (2023-2028)
  • Table 216. Blood Cancer Drugs MAbs/Targeted Therapies , by Region USD Million (2023-2028)
  • Table 217. Blood Cancer Drugs Immunotherapeutic , by Region USD Million (2023-2028)
  • Table 218. Blood Cancer Drugs: by Blood Cancer Type(USD Million)
  • Table 219. Blood Cancer Drugs Leukemia , by Region USD Million (2023-2028)
  • Table 220. Blood Cancer Drugs Lymphoma , by Region USD Million (2023-2028)
  • Table 221. Blood Cancer Drugs Myeloma , by Region USD Million (2023-2028)
  • Table 222. South America Blood Cancer Drugs, by Country USD Million (2023-2028)
  • Table 223. South America Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 224. South America Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 225. South America Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 226. Brazil Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 227. Brazil Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 228. Brazil Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 229. Argentina Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 230. Argentina Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 231. Argentina Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 232. Rest of South America Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 233. Rest of South America Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 234. Rest of South America Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 235. Asia Pacific Blood Cancer Drugs, by Country USD Million (2023-2028)
  • Table 236. Asia Pacific Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 237. Asia Pacific Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 238. Asia Pacific Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 239. China Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 240. China Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 241. China Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 242. Japan Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 243. Japan Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 244. Japan Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 245. India Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 246. India Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 247. India Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 248. South Korea Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 249. South Korea Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 250. South Korea Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 251. Taiwan Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 252. Taiwan Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 253. Taiwan Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 254. Australia Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 255. Australia Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 256. Australia Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 257. Rest of Asia-Pacific Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 258. Rest of Asia-Pacific Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 259. Rest of Asia-Pacific Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 260. Europe Blood Cancer Drugs, by Country USD Million (2023-2028)
  • Table 261. Europe Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 262. Europe Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 263. Europe Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 264. Germany Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 265. Germany Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 266. Germany Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 267. France Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 268. France Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 269. France Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 270. Italy Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 271. Italy Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 272. Italy Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 273. United Kingdom Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 274. United Kingdom Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 275. United Kingdom Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 276. Netherlands Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 277. Netherlands Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 278. Netherlands Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 279. Rest of Europe Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 280. Rest of Europe Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 281. Rest of Europe Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 282. MEA Blood Cancer Drugs, by Country USD Million (2023-2028)
  • Table 283. MEA Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 284. MEA Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 285. MEA Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 286. Middle East Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 287. Middle East Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 288. Middle East Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 289. Africa Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 290. Africa Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 291. Africa Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 292. North America Blood Cancer Drugs, by Country USD Million (2023-2028)
  • Table 293. North America Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 294. North America Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 295. North America Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 296. United States Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 297. United States Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 298. United States Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 299. Canada Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 300. Canada Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 301. Canada Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 302. Mexico Blood Cancer Drugs, by Drugs USD Million (2023-2028)
  • Table 303. Mexico Blood Cancer Drugs, by Treatment Approaches USD Million (2023-2028)
  • Table 304. Mexico Blood Cancer Drugs, by Blood Cancer Type USD Million (2023-2028)
  • Table 305. Blood Cancer Drugs Sales: by Drugs(k Tons)
  • Table 306. Blood Cancer Drugs Sales Rituaxan , by Region k Tons (2023-2028)
  • Table 307. Blood Cancer Drugs Sales Revlimid , by Region k Tons (2023-2028)
  • Table 308. Blood Cancer Drugs Sales Velcade , by Region k Tons (2023-2028)
  • Table 309. Blood Cancer Drugs Sales Vidaza , by Region k Tons (2023-2028)
  • Table 310. Blood Cancer Drugs Sales Pomalyst , by Region k Tons (2023-2028)
  • Table 311. Blood Cancer Drugs Sales Others , by Region k Tons (2023-2028)
  • Table 312. Blood Cancer Drugs Sales: by Treatment Approaches(k Tons)
  • Table 313. Blood Cancer Drugs Sales Chemotherapeutic , by Region k Tons (2023-2028)
  • Table 314. Blood Cancer Drugs Sales MAbs/Targeted Therapies , by Region k Tons (2023-2028)
  • Table 315. Blood Cancer Drugs Sales Immunotherapeutic , by Region k Tons (2023-2028)
  • Table 316. Blood Cancer Drugs Sales: by Blood Cancer Type(k Tons)
  • Table 317. Blood Cancer Drugs Sales Leukemia , by Region k Tons (2023-2028)
  • Table 318. Blood Cancer Drugs Sales Lymphoma , by Region k Tons (2023-2028)
  • Table 319. Blood Cancer Drugs Sales Myeloma , by Region k Tons (2023-2028)
  • Table 320. South America Blood Cancer Drugs Sales, by Country k Tons (2023-2028)
  • Table 321. South America Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 322. South America Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 323. South America Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 324. Brazil Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 325. Brazil Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 326. Brazil Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 327. Argentina Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 328. Argentina Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 329. Argentina Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 330. Rest of South America Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 331. Rest of South America Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 332. Rest of South America Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 333. Asia Pacific Blood Cancer Drugs Sales, by Country k Tons (2023-2028)
  • Table 334. Asia Pacific Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 335. Asia Pacific Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 336. Asia Pacific Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 337. China Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 338. China Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 339. China Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 340. Japan Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 341. Japan Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 342. Japan Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 343. India Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 344. India Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 345. India Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 346. South Korea Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 347. South Korea Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 348. South Korea Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 349. Taiwan Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 350. Taiwan Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 351. Taiwan Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 352. Australia Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 353. Australia Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 354. Australia Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 355. Rest of Asia-Pacific Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 356. Rest of Asia-Pacific Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 357. Rest of Asia-Pacific Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 358. Europe Blood Cancer Drugs Sales, by Country k Tons (2023-2028)
  • Table 359. Europe Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 360. Europe Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 361. Europe Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 362. Germany Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 363. Germany Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 364. Germany Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 365. France Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 366. France Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 367. France Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 368. Italy Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 369. Italy Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 370. Italy Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 371. United Kingdom Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 372. United Kingdom Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 373. United Kingdom Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 374. Netherlands Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 375. Netherlands Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 376. Netherlands Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 377. Rest of Europe Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 378. Rest of Europe Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 379. Rest of Europe Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 380. MEA Blood Cancer Drugs Sales, by Country k Tons (2023-2028)
  • Table 381. MEA Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 382. MEA Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 383. MEA Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 384. Middle East Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 385. Middle East Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 386. Middle East Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 387. Africa Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 388. Africa Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 389. Africa Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 390. North America Blood Cancer Drugs Sales, by Country k Tons (2023-2028)
  • Table 391. North America Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 392. North America Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 393. North America Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 394. United States Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 395. United States Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 396. United States Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 397. Canada Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 398. Canada Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 399. Canada Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 400. Mexico Blood Cancer Drugs Sales, by Drugs k Tons (2023-2028)
  • Table 401. Mexico Blood Cancer Drugs Sales, by Treatment Approaches k Tons (2023-2028)
  • Table 402. Mexico Blood Cancer Drugs Sales, by Blood Cancer Type k Tons (2023-2028)
  • Table 403. Research Programs/Design for This Report
  • Table 404. Key Data Information from Secondary Sources
  • Table 405. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Blood Cancer Drugs: by Drugs USD Million (2017-2022)
  • Figure 5. Global Blood Cancer Drugs: by Treatment Approaches USD Million (2017-2022)
  • Figure 6. Global Blood Cancer Drugs: by Blood Cancer Type USD Million (2017-2022)
  • Figure 7. South America Blood Cancer Drugs Share (%), by Country
  • Figure 8. Asia Pacific Blood Cancer Drugs Share (%), by Country
  • Figure 9. Europe Blood Cancer Drugs Share (%), by Country
  • Figure 10. MEA Blood Cancer Drugs Share (%), by Country
  • Figure 11. North America Blood Cancer Drugs Share (%), by Country
  • Figure 12. Global Blood Cancer Drugs: by Drugs k Tons (2017-2022)
  • Figure 13. Global Blood Cancer Drugs: by Treatment Approaches k Tons (2017-2022)
  • Figure 14. Global Blood Cancer Drugs: by Blood Cancer Type k Tons (2017-2022)
  • Figure 15. South America Blood Cancer Drugs Share (%), by Country
  • Figure 16. Asia Pacific Blood Cancer Drugs Share (%), by Country
  • Figure 17. Europe Blood Cancer Drugs Share (%), by Country
  • Figure 18. MEA Blood Cancer Drugs Share (%), by Country
  • Figure 19. North America Blood Cancer Drugs Share (%), by Country
  • Figure 20. Global Blood Cancer Drugs share by Players 2022 (%)
  • Figure 21. Global Blood Cancer Drugs share by Players (Top 3) 2022(%)
  • Figure 22. Global Blood Cancer Drugs share by Players (Top 5) 2022(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Johnson & Johnson Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Johnson & Johnson Inc. (United States) Revenue: by Geography 2022
  • Figure 26. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Amgen Inc. (United States) Revenue: by Geography 2022
  • Figure 28. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 30. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer, Inc. (United States) Revenue: by Geography 2022
  • Figure 32. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. AbbVie Inc. (United States) Revenue: by Geography 2022
  • Figure 34. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2022
  • Figure 36. Celgene Corporation (Switzerland) Revenue, Net Income and Gross profit
  • Figure 37. Celgene Corporation (Switzerland) Revenue: by Geography 2022
  • Figure 38. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 39. AstraZeneca plc (United Kingdom) Revenue: by Geography 2022
  • Figure 40. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 41. Novartis International AG (Switzerland) Revenue: by Geography 2022
  • Figure 42. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 43. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2022
  • Figure 44. Global Blood Cancer Drugs: by Drugs USD Million (2023-2028)
  • Figure 45. Global Blood Cancer Drugs: by Treatment Approaches USD Million (2023-2028)
  • Figure 46. Global Blood Cancer Drugs: by Blood Cancer Type USD Million (2023-2028)
  • Figure 47. South America Blood Cancer Drugs Share (%), by Country
  • Figure 48. Asia Pacific Blood Cancer Drugs Share (%), by Country
  • Figure 49. Europe Blood Cancer Drugs Share (%), by Country
  • Figure 50. MEA Blood Cancer Drugs Share (%), by Country
  • Figure 51. North America Blood Cancer Drugs Share (%), by Country
  • Figure 52. Global Blood Cancer Drugs: by Drugs k Tons (2023-2028)
  • Figure 53. Global Blood Cancer Drugs: by Treatment Approaches k Tons (2023-2028)
  • Figure 54. Global Blood Cancer Drugs: by Blood Cancer Type k Tons (2023-2028)
  • Figure 55. South America Blood Cancer Drugs Share (%), by Country
  • Figure 56. Asia Pacific Blood Cancer Drugs Share (%), by Country
  • Figure 57. Europe Blood Cancer Drugs Share (%), by Country
  • Figure 58. MEA Blood Cancer Drugs Share (%), by Country
  • Figure 59. North America Blood Cancer Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Johnson & Johnson Inc. (United States)
  • Amgen Inc. (United States)
  • Bayer AG (Germany)
  • Pfizer, Inc. (United States)
  • AbbVie Inc. (United States)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Celgene Corporation (Switzerland)
  • AstraZeneca plc (United Kingdom)
  • Novartis International AG (Switzerland)
  • GlaxoSmithKline PLC (United Kingdom)
Additional players considered in the study are as follows:
Merck & Co., Inc. (Unites States) , Eli Lily & Co. (United States)
Select User Access Type

Key Highlights of Report


Jun 2023 200 Pages 82 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Blood Cancer Drugs research Quantitative research analysis
Global Blood Cancer Drugs research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Blood Cancer Drugs market are Johnson & Johnson Inc. (United States), Amgen Inc. (United States), Bayer AG (Germany), Pfizer, Inc. (United States), AbbVie Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Celgene Corporation (Switzerland), AstraZeneca plc (United Kingdom), Novartis International AG (Switzerland) and GlaxoSmithKline PLC (United Kingdom), to name a few.
North America is dominating the Blood Cancer Drugs Market.
"High Cost of Drug Development and the Threat of Failure" is seen as one of the major challenges by many Industry Players of Blood Cancer Drugs Market
The Blood Cancer Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Blood Cancer Drugs market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Blood Cancer Drugs research Report?

Have a Query? Click Here

Other Related Reports

Anticancer Drugs Comprehensive Study by Application (Hospitals & Clinics, Oncological Research Centres), Drug Type (Targeted Drugs, Cytotoxic Drugs), Distribution Chanel (Direct, Indirect), Treatment...
$ 3650
CBD Hemp Oil Comprehensive Study by Type (Inorganic Source, Organic Source), Application (Pharmaceuticals Industry, Food Industry, Cosmetic Industry, Others) Players and Region - Global Market Outloo...
$ 3500
Male Hypogonadism Comprehensive Study by Type (Primary hypogonadism(Genetic, congenital), Secondary hypogonadism(Kallman syndrome, pituitary gland tumour)), Application (Kallmann Syndrome, Klinefelte...
$ 3750
Insomnia Drugs Comprehensive Study by Type (Prescription-based Drugs, OTC Drugs, Herbal Drugs), Application (Hospitals, Clinics, Research Centres, Others), Distribution Channel (Retail Pharmacies, On...
$ 3450
Thrombin Comprehensive Study by Type (Bovine Thrombin, Human Thrombin, Recombinant Thrombin), Dosage Form (Powder Form, Solution Form), End User (Hospitals, Diagnostics Centers & Clinics, Ambulatory ...
$ 3450
Heavy Metal Poisoning Drugs Comprehensive Study by Type (ALN-TMP, Deferasirox, Deferoxamine Mesylate, Emeramide, Others), Application (Arsenic Toxicity, Chromium Toxicity, Copper Toxicity, Lead Toxic...
$ 3750